Traduction de «intranet was launched in » (Néerlandais → Français) :

For optimal information flow and the active involvement of all employees, an intranet was launched in October 2007.
For optimal information flow and the active involvement of all employees, an intranet was launched in October 2007.

Enhancing the organisation’s image and improving online communication In 2007 an intranet was launched in cooperation with the Communication & Scientific Support service and there are plans to develop a brandnew website with the BUM department that will group existing sites and optimise internal and external communication.
Enhancing the organisation’s image and improving online communication In 2007 an intranet was launched in cooperation with the Communication & Scientific Support service and there are plans to develop a brandnew website with the BUM department that will group existing sites and optimise internal and external communication.

Extavia (USD 26 million), for patients with relapsing forms of multiple sclerosis (MS), was first launched in the European Union in early 2009 and is now available in more than 15 countries, including the US where it was launched recently after regulatory approval was granted in August 2009.
Extavia (USD 26 millions), pour les malades atteints de formes cycliques de sclérose en plaques (SEP), a été commercialisé d’abord dans l’Union européenne début 2009.

Of particular note is the third quarter launch of enoxaparin, the first-to-market generic version of the anti-thrombotic drug Lovenox®, which was the most successful injectables launch in the US ever.
Le lancement au troisième trimestre d’énoxaparine, la première version générique du médicament antithrombique Lovenox® mérite une mention particulière, car jamais la sortie d’un injectable n’a connu un tel succès aux Etats- Unis.

Afinitor (USD 12 million), an oral inhibitor of the mTOR pathway, was launched in the US after regulatory approval was granted in March as the first therapy for patients with advanced renal cell carcinoma (kidney cancer) after failure of treatment with sunitinib or sorafenib.
Afinitor (USD 12 millions), inhibiteur par voie orale de la voie mTOR, a été lancé aux Etats-Unis après avoir reçu, en mars, son homologation en tant que traitement du carcinome avancé des cellules rénales (cancer du rein) après échec d’un traitement par sunitinib ou sorafenib.

In spite of there having been no advertising and hardly any information spread about its launch, the Forum was highly successful from the very start: not only did it attract a great number of visitors and messages, but, more importantly, a genuine “support community” was found to emerge as a result of the exchange of views and feelings.
Dès son ouverture, alors qu’aucune publicité ni communication particulière n’avait été faite sur sa création, le forum a rencontré un franc succès: un grand nombre de visiteurs et de messages mais surtout la découverte de la création d’une authentique « communauté de soutien » au travers des réponses échangées.

Diovan (USD 4.4 billion, +5% lc) achieved solid worldwide growth, driven by expansion in Japan, which accounts for approximately 20% of net sales and where the Co-Dio diuretic combination therapy was launched in 2009.
Diovan (USD 4,4 milliards, +5% en m. l) a enregistré une solide croissance mondiale, emmenée par l’expansion au Japon, qui compte pour environ 20% du chiffre d’affaires net, et où Co-Dio, un traitement associé à un diurétique, a été lancé en 2009.

Pharmaceuticals Ilaris (canakinumab, ACZ885), a human antibody targeting IL-1 beta, was launched in the US and Switzerland in August 2009 as a new therapy to treat children as young as age four and adults with CAPS (Cryopyrin-Associated Periodic Syndrome), a rare life-long and potentially fatal auto-inflammatory disease.
Pharmaceuticals Ilaris (canakinumab, ACZ885), un anticorps humain ciblant IL-1 bêta, a été lancé en août aux Etats-Unis et en Suisse comme nouveau traitement chez les enfants de plus de quatre ans et les adultes atteints des syndromes périodiques associés à la cryopyrine (CAPS), une maladie auto-inflammatoire sévère durant toute la vie et potentiellement mortelle.

Rasilez was launched in Japan in October 2009.
Rasilez a été lancé au Japon en octobre 2009.

Exforge HCT, which adds a diuretic to this combination, was launched in the US after regulatory approval in April 2009 as a high blood pressure therapy with three medicines in one pill.
Exforge HCT, qui ajoute un diurétique à cette association, a été lancé aux Etats-Unis où il a été autorisé, en avril 2009, en tant que traitement contre l’hypertension associant trois médicaments en un comprimé unique.